Across TCGA pan-cancer cohorts, NDUFA4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NDUFA4 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NDUFA4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated NDUFA4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where NDUFA4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.955	0.787	.008	30	view →
LUAD	OS	Tertile	All	0.560	0.895	.011	14	view →
LSCC	DFS	Median	III,IV	1.000	0.606	.006	5	view →
GBM	DFS	Median	All	0.865	0.638	.002	5	view →
CCRCC	DFS	Tertile	All	0.879	0.582	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: NDUFA4 tumor-vs-normal RNA expression · all NDUFA4 data types